Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Estimating the Prevalence of Ovarian Cancer Symptoms in Women Aged 50 Years or Older: Problems and Possibilities.

Sun Z, Gilbert L, Ciampi A, Kaufman JS, Basso O.

Am J Epidemiol. 2016 Nov 1;184(9):670-680. Epub 2016 Oct 13.

PMID:
27737840
2.

The Association Between Body Mass Index and Presenting Symptoms in African American Women with Ovarian Cancer.

Erondu CO, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Peters E, Schwartz AG, Terry PD, Wallace K, Akushevich L, Wang F, Crankshaw S, Berchuck A, Schildkraut JM, Moorman PG.

J Womens Health (Larchmt). 2016 Jun;25(6):571-8. doi: 10.1089/jwh.2015.5359. Epub 2016 Feb 17.

PMID:
26886855
3.

Effects of Demographics and OTC Analgesics on Ovarian Cancer Symptoms.

Lowe KA, Andersen MR, Kane JC, Robertson MD, Goff BA.

J Nurse Pract. 2013 Jan;9(1):28-33.

4.

Modified Goff Symptom Index: Simple triage tool for ovarian malignancy.

Shetty J, Priyadarshini P, Pandey D, Manjunath AP.

Sultan Qaboos Univ Med J. 2015 Aug;15(3):e370-5. doi: 10.18295/squmj.2015.15.03.011. Epub 2015 Aug 24.

5.

Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome.

Wang Y, Ye Y, Lin J, Meyer L, Wu X, Lu K, Liang D.

Mol Carcinog. 2015 Jun;54(6):430-9. doi: 10.1002/mc.22111. Epub 2013 Nov 19.

6.

Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.

Shilpa V, Bhagat R, Premalata CS, Pallavi VR, Ramesh G, Krishnamoorthy L.

Indian J Med Res. 2014 Nov;140(5):616-23.

7.
8.

Clinico-histopathological analysis of neoplastic and non-neoplastic lesions of the ovary: a 3-year prospective study in dhule, north maharashtra, India.

S N K, N V D, P N D, D B N, K H S.

J Clin Diagn Res. 2014 Aug;8(8):FC04-7. doi: 10.7860/JCDR/2014/8911.4709. Epub 2014 Aug 20.

9.

Irritable bowel syndrome: a clinical review.

Soares RL.

World J Gastroenterol. 2014 Sep 14;20(34):12144-60. doi: 10.3748/wjg.v20.i34.12144. Review.

10.

WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.

King ML, Lindberg ME, Stodden GR, Okuda H, Ebers SD, Johnson A, Montag A, Lengyel E, MacLean Ii JA, Hayashi K.

Oncogene. 2015 Jun;34(26):3452-62. doi: 10.1038/onc.2014.277. Epub 2014 Sep 1.

11.

Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials.

Donovan KA, Donovan HS, Cella D, Gaines ME, Penson RT, Plaxe SC, von Gruenigen VE, Bruner DW, Reeve BB, Wenzel L.

J Natl Cancer Inst. 2014 Jul 8;106(7). pii: dju128. doi: 10.1093/jnci/dju128. Print 2014 Jul. Review.

12.

Diagnostic utility of PAX8 in differentiation of mullerian from non-mullerian tumors.

Heidarpour M, Tavanafar Z.

Adv Biomed Res. 2014 Mar 25;3:96. doi: 10.4103/2277-9175.129366. eCollection 2014.

13.

Crowdsourcing awareness: exploration of the ovarian cancer knowledge gap through Amazon Mechanical Turk.

Carter RR, DiFeo A, Bogie K, Zhang GQ, Sun J.

PLoS One. 2014 Jan 22;9(1):e85508. doi: 10.1371/journal.pone.0085508. eCollection 2014.

14.

Value of symptom-triggered diagnostic evaluation for ovarian cancer.

Andersen MR, Lowe KA, Goff BA.

Obstet Gynecol. 2014 Jan;123(1):73-9. doi: 10.1097/AOG.0000000000000051.

15.

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.

Pitta Dda R, Sarian LO, Barreta A, Campos EA, Andrade LL, Fachini AM, Campbell LM, Derchain S.

BMC Cancer. 2013 Sep 18;13:423. doi: 10.1186/1471-2407-13-423.

16.

Experience of symptoms indicative of gynaecological cancers in UK women.

Low EL, Simon AE, Waller J, Wardle J, Menon U.

Br J Cancer. 2013 Aug 20;109(4):882-7. doi: 10.1038/bjc.2013.412. Epub 2013 Jul 23.

17.

Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis.

Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, Dahmoush L, Penedo F, Lucci J 3rd, Thaker PH, Mendez L, Sood AK, Slavich GM, Lutgendorf SK.

Cancer. 2013 Sep 1;119(17):3234-41. doi: 10.1002/cncr.28188. Epub 2013 Jun 24.

18.

Impact of a computer-based diagnostic decision support tool on the differential diagnoses of medicine residents.

Feldman MJ, Hoffer EP, Barnett GO, Kim RJ, Famiglietti KT, Chueh HC.

J Grad Med Educ. 2012 Jun;4(2):227-31. doi: 10.4300/JGME-D-11-00180.1.

19.

Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer.

Sailors MH, Bodurka DC, Gning I, Ramondetta LM, Williams LA, Mendoza TR, Agarwal S, Sun CC, Cleeland CS.

Gynecol Oncol. 2013 Aug;130(2):323-8. doi: 10.1016/j.ygyno.2013.05.009. Epub 2013 May 15.

20.

Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers.

Dao MD, Alwan LM, Gray HJ, Tamimi HK, Goff BA, Liao JB.

Gynecol Oncol. 2013 Aug;130(2):295-9. doi: 10.1016/j.ygyno.2013.04.055. Epub 2013 Apr 28.

Supplemental Content

Support Center